Vericel (NASDAQ:VCEL) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Vericel (NASDAQ:VCEL - Get Free Report) announced its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14), Zacks reports. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $52.60 million for the quarter, compared to the consensus estimate of $53.86 million. During the same quarter last year, the firm posted ($0.08) earnings per share. The company's revenue was up 2.6% compared to the same quarter last year. Vericel updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Vericel Trading Down 2.5%

Shares of VCEL traded down $1.07 during mid-day trading on Thursday, hitting $41.23. The company's stock had a trading volume of 43,684 shares, compared to its average volume of 405,823. The firm has a 50-day simple moving average of $42.76 and a 200 day simple moving average of $51.15. The firm has a market capitalization of $2.07 billion, a P/E ratio of 685.61 and a beta of 1.31. Vericel has a 1-year low of $37.39 and a 1-year high of $63.00.

Insider Activity at Vericel

In related news, CEO Dominick Colangelo sold 24,850 shares of the business's stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $41.89, for a total value of $1,040,966.50. Following the transaction, the chief executive officer now owns 260,354 shares in the company, valued at approximately $10,906,229.06. The trade was a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

VCEL has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of Vericel in a report on Friday, February 28th. Canaccord Genuity Group raised their price objective on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Vericel in a research report on Wednesday, January 15th. StockNews.com downgraded Vericel from a "hold" rating to a "sell" rating in a research report on Monday. Finally, Truist Financial dropped their price objective on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $60.86.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.